ValuEngine cut shares of HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) from a sell rating to a strong sell rating in a research note issued to investors on Thursday.

A number of other brokerages also recently issued reports on HTGM. Zacks Investment Research raised HTG Molecular Diagnostics from a hold rating to a buy rating and set a $4.50 price objective for the company in a research report on Thursday, May 11th. Rodman & Renshaw raised their price objective on HTG Molecular Diagnostics from $4.50 to $6.00 and gave the stock a buy rating in a research report on Tuesday, May 16th. Finally, HC Wainwright set a $6.00 price objective on HTG Molecular Diagnostics and gave the stock a buy rating in a research report on Wednesday, August 9th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and two have assigned a buy rating to the company’s stock. The company presently has a consensus rating of Hold and a consensus price target of $5.75.

HTG Molecular Diagnostics (NASDAQ:HTGM) opened at 1.90 on Thursday. The company’s 50 day moving average is $2.27 and its 200 day moving average is $3.38. HTG Molecular Diagnostics has a 12-month low of $1.20 and a 12-month high of $13.25. The company’s market cap is $21.75 million.

HTG Molecular Diagnostics (NASDAQ:HTGM) last issued its quarterly earnings data on Tuesday, August 8th. The medical research company reported ($0.60) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.60). The firm had revenue of $1.76 million during the quarter, compared to the consensus estimate of $1.80 million. HTG Molecular Diagnostics had a negative return on equity of 1,538.49% and a negative net margin of 432.74%. Analysts forecast that HTG Molecular Diagnostics will post ($2.29) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “HTG Molecular Diagnostics, Inc. (HTGM) Downgraded by ValuEngine” was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this report on another site, it was illegally stolen and reposted in violation of international trademark & copyright law. The legal version of this report can be read at https://www.thecerbatgem.com/2017/08/28/htg-molecular-diagnostics-inc-htgm-downgraded-by-valuengine.html.

In other HTG Molecular Diagnostics news, major shareholder Holdings A/S Novo sold 47,162 shares of HTG Molecular Diagnostics stock in a transaction dated Wednesday, August 23rd. The stock was sold at an average price of $2.02, for a total value of $95,267.24. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders have sold a total of 1,659,998 shares of company stock valued at $3,073,696 over the last three months. Corporate insiders own 7.60% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC increased its position in HTG Molecular Diagnostics by 32.3% in the fourth quarter. Renaissance Technologies LLC now owns 58,200 shares of the medical research company’s stock valued at $130,000 after buying an additional 14,206 shares in the last quarter. UBS Group AG purchased a new position in HTG Molecular Diagnostics during the first quarter valued at $137,000. Two Sigma Securities LLC purchased a new position in HTG Molecular Diagnostics during the first quarter valued at $150,000. Granahan Investment Management Inc. MA purchased a new position in HTG Molecular Diagnostics during the first quarter valued at $228,000. Finally, Vanguard Group Inc. increased its position in HTG Molecular Diagnostics by 38.9% in the second quarter. Vanguard Group Inc. now owns 135,234 shares of the medical research company’s stock valued at $359,000 after buying an additional 37,841 shares in the last quarter. 21.67% of the stock is owned by institutional investors.

About HTG Molecular Diagnostics

HTG Molecular Diagnostics, Inc is a commercial-stage company that develops and markets a technology platform to facilitate the routine use of complex molecular profiling. The Company’s HTG Edge and HTG EdgeSeq platforms, consisting of instrumentation, consumables and software analytics, are used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Stock Ratings for HTG Molecular Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics Inc. and related stocks with our FREE daily email newsletter.